"This is a drug for people who have viral resistance, who haven't been able to benefit from advances in HIV therapy. For some of the oldest people living with HIV, that can be an unsatisfying and potentially challenging scenario: Once-a-day pills used by some younger patients are not always effective in older groups. That's because early HIV treatments may have led to drug resistance in those older groups, requiring them to take highly specialized, multi-pill regimens now."
"While modern medicines have improved the lives of people with HIV, such that they can suppress the virus and not pass it on to others, the success of therapy relies on specific regimens tailored to each individual patient. The clinical trial is testing a pill called BIC/LEN, which combines the antiviral drugs bictegravir and lenacapavir. The researchers hope it will become of a more convenient daily routine for older people living with HIV."
A clinical trial demonstrates that BIC/LEN, a single daily pill combining bictegravir and lenacapavir, provides effective HIV treatment for older patients living with the virus. Many people who have lived with HIV for decades developed drug resistance from early treatments, forcing them to take complicated multi-pill regimens that younger patients no longer need. This new formulation represents a significant advancement for this population, offering simplified treatment without sacrificing efficacy. The trial included the oldest group ever tested for an HIV drug, with participants averaging 60 years old and some in their eighties. The medication addresses a gap in HIV therapy where standard once-daily pills prove ineffective for those with resistant strains.
Read at www.dw.com
Unable to calculate read time
Collection
[
|
...
]